ReNeuron is a developer of stem cell therapies, with its lead human retinal progenitor cells (hRPC) candidate undergoing a Phase IIa study for the rare and progressive eye disease, Retinitis Pigmentosa (RP). In this note, we make forecast changes in response to the company’s strategic shift, cover recent competitor data for RP, and provide details on the exosome platform. Our valuation analysis has refocused solely on the hRPC programme, and implies an intrinsic value of 177p/share (vs. 310p/sha ....
19 Aug 2020
Refocus on hRPC drives forecast changes
Sign up to access
Get access to our full offering from over 30 providers
Get access to our full offering from over 30 providers
Refocus on hRPC drives forecast changes
ReNeuron Group plc (RENE:LON) | 3.0 0 0.0% | Mkt Cap: 1.74m
- Published:
19 Aug 2020 -
Author:
Edward Thomason -
Pages:
3
ReNeuron is a developer of stem cell therapies, with its lead human retinal progenitor cells (hRPC) candidate undergoing a Phase IIa study for the rare and progressive eye disease, Retinitis Pigmentosa (RP). In this note, we make forecast changes in response to the company’s strategic shift, cover recent competitor data for RP, and provide details on the exosome platform. Our valuation analysis has refocused solely on the hRPC programme, and implies an intrinsic value of 177p/share (vs. 310p/sha ....